Trial Profile

A Sequential, Open-Label Study of the Pharmacokinetics and Safety of Intravenous Carbamazepine Relative to Oral Carbamazepine in Adult Patients With Epilepsy.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 May 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carbamazepine (Primary) ; Carbamazepine
Indications Epilepsy; Generalised seizures; Partial epilepsies; Tonic-clonic epilepsy
Focus Adverse reactions; Pharmacokinetics
Sponsors Lundbeck A/S

28 Apr 2017 Results assessing the the pharmacokinetics of Capitsol in carbamazepine(CBZ)-treated patients with epilepsy by renal function status, presented at the 69th Annual Meeting of the American Academy of Neurology.
28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
28 Apr 2017 Results comparing pharmacokinetics of oral carbamazepine (CBZ) and intravenous CBZ in patients by renal function status, presented at the 69th Annual Meeting of the American Academy of Neurology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com